Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9438229 | 0.99 | PTAFR (0.98) | PTAFR | |
| Hydrochloric Acid SCHEMBL9438308 | 0.94 | PTAFR (0.89) | PTAFR | |
| Hydrochloric Acid SCHEMBL10396468 | 0.91 | PTAFR (0.84) | PTAFR | |
| SCHEMBL10618457 | 0.90 | PTAFR (0.82) | PTAFR | |
| Hydrochloric Acid SCHEMBL10397529 | 0.90 | PTAFR (0.82) | PTAFR | |
| Hydrochloric Acid SCHEMBL9438209 | 0.89 | PTAFR (0.81) | PTAFR | |
| Hydrochloric Acid SCHEMBL10397113 | 0.89 | PTAFR (0.81) | PTAFR | |
| Hydrochloric Acid SCHEMBL9438350 | 0.89 | PTAFR (0.80) | PTAFR | |
| Hydrochloric Acid SCHEMBL9438254 | 0.88 | PTAFR (0.78) | PTAFR | |
| SCHEMBL9206505 | 0.88 | PTAFR (0.78) | PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | claimed |
| EP-0357550-B1 | New use of 5-heteroaryl- or 5-aryl-substituted imidazo [2,1-a] isoquinolines | SANDOZ AG (CH) | 1994-03-02 | — | — | EP | claimed |
| EP-0258175-B1 | 5-hetero- or aryl-substituted-imidazo[2,1-a]isoquinolines | SANDOZ AG (CH) | 1992-04-01 | — | — | EP | claimed |
| EP-0469477-A1 | Antiallergic combination | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-05 | — | — | EP | claimed |
| EP-0357550-A2 | New use of 5-heteroaryl- or 5-aryl-substituted imidazo [2,1-a] isoquinolines | SANDOZ AG (CH) | 1990-03-07 | — | — | EP | claimed |
| WO-1988000587-A2 | 5-HETERO- OR ARYL-SUBSTITUTED-IMIDAZO[2,1-a]ISOQUINOLINES | SANDOZ AG (CH) | 1988-01-28 | — | — | WO | claimed |
| JP-2073016-A | — | — | None | — | — | JP | disclosed |
| EP-0469477-B1 | Antiallergic combination | HOFFMANN LA ROCHE (CH) | 1995-09-20 | — | — | EP | disclosed |
| EP-0357550-B1 | New use of 5-heteroaryl- or 5-aryl-substituted imidazo [2,1-a] isoquinolines | SANDOZ AG (CH) | 1994-03-02 | — | — | EP | disclosed |
| US-5227378-A | Synergistic mixture of platelet activating factor and leukotriene antagonists | HOFFMANN-LA ROCHE INC. (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0469477-A1 | Antiallergic combination | F. HOFFMANN-LA ROCHE AG (CH) | 1992-02-05 | — | — | EP | disclosed |
| JP-H0273016-A | USE OF 5-HETEROARYL OR 5-ARYL SUBSTITUTED IMIDAZO(2,1-A) ISOQUINOLINE | SANDOZ AG | 1990-03-13 | — | — | JP | disclosed |